-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Azacitidine in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azacitidine in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Metastatic Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Metastatic Uveal Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Metastatic Uveal Melanoma Drug Details: Cemiplimab (Libtayo) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in T-Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in T-Cell Lymphomas Drug Details: Cemiplimab (Libtayo) is an anti-neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Natural Killer Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Natural Killer Cell Lymphomas Drug Details: Cemiplimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Metastatic Pancreatic Cancer Drug Details: Cemiplimab (Libtayo) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Relapsed Multiple Myeloma Drug Details: Cemiplimab (Libtayo) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Refractory Multiple Myeloma Drug Details: Cemiplimab (Libtayo) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Hormone-Sensitive Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Hormone-Sensitive Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Hormone-Sensitive Prostate Cancer Drug Details: Cemiplimab (Libtayo) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Cemiplimab (Libtayo)...
-
Sector Analysis
Petrochemicals Capacity and Capital Expenditure Outlook by Region, Countries, Companies, Commodity, Projects and Forecast to 2030
Petrochemicals Capacity & Capital Expenditure (Capex) Overview The petrochemicals capacity was 2600.06 million tonnes per annum (mtpa) in 2023. Asia, the Middle East, and the Former Soviet Union are the top regions contributing to capacity additions in the upcoming years. In the Middle East, most capacity additions are in Iran while in FSU, the majority of capacity additions are in Russia. Petrochemicals Capacity and Capex Outlook, 2023-2030 (mtpa) Buy the Full Report for More Insights on Petrochemicals Capacity and Capex...